Authera is a pre-clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic biologics.
A high-end unique technology platform guiding design and selection
Our know-how is based on an in-depth molecular and cellular understanding of crucial biological processes, involving interactions between the neonatal Fc receptor (FcRn) and its ligands, IgG antibodies and albumin.
Our platform combines unique biochemical and cellular assays with state-of-the-art in vivo models, to guide pre-clinical design and selection.
The platform
Authera has two lead pre-clinical development programs.
Pre-clinical pipeline
AuT-1
Focus area
Exudative eye diseases
Partner with
AuT-2
Undisclosed
Business
Authera is science-driven, as we learn by nature.
We strongly believe in partnership with academia, biotech and pharmaceutical industry.
Authera has the expertise needed to guide design and selection of FcRn-binding molecules. As such, a partnership with us will educate and de-risk product development towards clinical evaluation.
Team
Simone Mester, PhD
CEO & Co-founder
Torleif T. Gjølberg, PhD
CSO & Co-founder
Jan Terje Andersen, PhD
Chairman & Co-founder
Inger Sandlie, PhD
Board member & Co-founder
Gaia Calamera, PhD
Scientist
Eirik Sundlisæter, MD PhD
Scientist
Jenny Skjermo Telstad, MSc
Research Assistant
